Ipilimumab, a monoclonal antibody against CTLA-4 (Figure 1), was the first drug to demonstrate a significant improvement in OS of advanced melanoma in a phase 3 study (Table 1) [16]. The gene discussed is CTLA4; the disease is melanoma.